LEAP THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.25 USD | +2.52% |
|
+16.07% | -21.59% |
| Sales 2024 * | - | Sales 2025 * | 25.86M 2.16B | Capitalization | 83.21M 6.94B |
|---|---|---|---|---|---|
| Net income 2024 * | -69M -5.76B | Net income 2025 * | -69M -5.76B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.22 x |
| P/E ratio 2024 * |
-1.44
x | P/E ratio 2025 * |
-2.18
x | Employees | 54 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Leap Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +2.52% | ||
| 1 week | +16.07% | ||
| Current month | +22.18% | ||
| 1 month | +22.18% | ||
| 3 months | +33.20% | ||
| 6 months | +132.14% | ||
| Current year | -21.59% |
1 week
2.99
3.39
1 month
2.424.39
Current year
2.135.00
1 year
1.2410.20
3 years
1.2441.70
5 years
1.2441.70
10 years
1.24102.50
| Managers | Title | Age | Since |
|---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 01/11/01 |
Chris Mirabelli
CHM | Chairman | 69 | 01/11/01 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 24/20/24 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 01/16/01 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 01/17/01 |
Chris Mirabelli
CHM | Chairman | 69 | 01/11/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 3.25 | +2.52% | 403,202 |
| 25/24/25 | 3.17 | -3.65% | 213,233 |
| 24/24/24 | 3.29 | +2.81% | 200,614 |
| 23/24/23 | 3.2 | -0.31% | 89,131 |
| 22/24/22 | 3.21 | +14.64% | 328,700 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-related protein 1 (DKK1) protein. DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. Its second clinical-stage program is FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. It also has two preclinical antibody programs, FL-302 and FL-501. FL-302 is a Claudin18.2/CD137 (also known as 4-1BB) bispecific antibody that is in preclinical development. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Calendar
15/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.25
USD
Average target price
11.75
USD
Spread / Average Target
+261.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.59% | 83.21M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.38% | 22.15B | |
| -17.37% | 21.02B | |
| -8.77% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LPTX Stock
